CoChat

Transparency of clinical trials in pancreatic cancer: An analysis of availability of trial results from the ClinicalTrials.gov database

Huang, Ren-Qian, Zhou, You, Zheng, Hai-Xia, Wang, Dan, Zheng, Xiao-Yi, Li, Zhao-Shen, Hu, Liang-Hao · 2023 · Frontiers in Oncology
Cited by 6

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Pancreatic cancer (PC) is a highly malignant tumor of the digestive system. As clinical trials involving PC are increasingly being conducted, the transparency of the generated data has become an important issue of concern. In other areas of medicine, clinical trial transparency presents a worrying state of affairs. However, at present, there has been no study examining the transparency of data derived from PC clinical trials. Methods: A comprehensive search was conducted in the ClinicalTrial.gov database for clinical trials investigating pancreatic cancer as of June 2022. We examined the availability of clinical trial results and recorded the characteristics of the trials. Results: A total of 856 trials were included in this study, of which 668 were completed and 188 were terminated or suspended. The results of 626 trials (73.13%) were available, of these 230 trials (26.87%) did not disclose any information on the trial data in any form. The publication rate for trials with available results was 86.10%, but the report rate on ClinicalTrial.gov was only 39.78%. Conclusion: Although approximately 90% of clinical trial investigating interventions on patients with PC have published study results, 30% of trials did not report any findings, and the disclosure of trial results from ClinicalTrial.gov was unsatisfactory. In general, there is still room for improvement in the transparency of PC clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2022.1026268

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 19

  1. Zarin, 2007, Issues in the registration of clinical trials, Jama., 297, 10.1001/jama.297.19.2112 · DOI · Paper page
  2. Dal-Re, 2015, Improving transparency of clinical trials, Trends Pharmacol Sci, 36, 10.1016/j.tips.2014.10.012 · DOI
  3. Saito, 2014, How frequently do the results from completed US clinical trials enter the public domain, –A Stat Anal ClinicalTrials.gov database. PloS One, 9, 10.1371/journal.pone.0101826 · DOI · Paper page
  4. Dal-Ré, 2016, Prevention of selective outcome reporting: let us start from the beginning, Eur J Clin Pharmacol, 72, 10.1007/s00228-016-2112-3 · DOI
  5. Garg, 2022, Gastroenterology clinical trials transparency: An analysis of publication rates from the ClinicalTrials, gov Database. Am J Gastroenterol, 117, 10.14309/ajg.0000000000001517 · DOI
  6. Garg, 2022, Clinical trial transparency in gastrointestinal endoscopy research, Endoscopy., 55, 36, 10.1055/a-1855-7870 · DOI
  7. Rahib, 2014, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states, Cancer Res, 74, 10.1158/0008-5472.CAN-14-0155 · DOI · Paper page
  8. Moore, 2019, Pancreatic cancer, Jama., 322, 1426, 10.1001/jama.2019.14699 · DOI
  9. Chen, 2016, Cancer statistics in China, 2015, CA: Cancer J Clin, 66, 10.3322/caac.21338 · DOI · Paper page
  10. Janssen, 2022, Neoadjuvant radiotherapy after (m)FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: A TAPS consortium study, J Natl Compr Cancer Network JNCCN., 20, 783, 10.6004/jnccn.2022.7008 · DOI
  11. Pion, 2022, 3D in vivo models for translational research on pancreatic cancer: The chorioallantoic membrane (CAM) model, Cancers., 14, 10.3390/cancers14153733 · DOI
  12. Chuong, 2022, Induction chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy for inoperable pancreas cancer, Front Oncol, 12, 10.3389/fonc.2022.888462 · DOI
  13. Uson Junior, 2022, Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: A contemporary analysis, Sci Rep, 12, 13592, 10.1038/s41598-022-17743-6 · DOI
  14. Pranić, 2016, Changes to registration elements and results in a cohort of clinicaltrials.gov trials were not reflected in published Articles, J Clin Epidemiol, 70, 26, 10.1016/j.jclinepi.2015.07.007 · DOI
  15. Huić, 2011, Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy, PloS One, 6, 10.1371/journal.pone.0025258 · DOI · Paper page
  16. Roberto, 2018, Transparency in ovarian cancer clinical trial results: ClinicalTrials.gov versus PubMed, embase and Google scholar, J Ovarian Res, 11, 28, 10.1186/s13048-018-0404-1 · DOI
  17. Nguyen, 2013, Public availability of results of trials assessing cancer drugs in the united states, J Clin Oncol Off J Am Soc Clin Oncol, 31, 2998, 10.1200/JCO.2012.46.9577 · DOI · Paper page
  18. Tempero, 2021, Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology, J Natl Compr Cancer Network JNCCN, 19, 10.6004/jnccn.2021.0017 · DOI · Paper page
  19. Okusaka, 2020, Recent advances in chemotherapy for pancreatic cancer: Evidence from Japan and recommendations in guidelines, J gastroenterology., 55, 10.1007/s00535-020-01666-y · DOI

Cited by

See all 6

Metadata

Authors
Huang, R.-Q., Zhou, Y., Zheng, H.-X., Wang, D., Zheng, X.-Y., Li, Z.-S., & Hu, L.-H.
Venue
Frontiers in Oncology
Published
2023-01-06
Volume
12
ISSN
2234-943X
Cited by
6
References
3
Funders
National Natural Science Foundation of China (No. 82070664)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.